Improving access to immunotherapy in low- and middle-income countries
Authors:
- 13 January 2022
- journal article
- editorial
- Published by Elsevier in Annals of Oncology
- Vol. 33 (4) , 360-361
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective TreatmentsJournal of Clinical Oncology, 2021
- Alternative dosing regimens for atezolizumab: right dose, wrong frequencyCancer Chemotherapy and Pharmacology, 2019
- Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsClinical Cancer Research, 2015
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialJournal of Clinical Oncology, 2015
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010